We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Commercial Testing Service Available for Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 17 Jul 2012
A commercial testing service is now available for Acute Myeloid Leukemia (AML) patients for any hospital in Europe. More...


The comprehensive molecular diagnostic testing service provides eight of the most powerful diagnostic markers to perform accurate AML molecular subtyping, necessary to stratify and optimize treatment for each patient.

The assay menu consists of the AMLprofiler (Skyline Diagnostics; Rotterdam, The Netherlands) and the Leukostrat fms-like tyrosine kinase receptor-3 (FLT3) and Nucleophosmin (NPM1) Mutation Testing (Laboratory for Personalized Molecular Medicine [LabPMM]; Martinsried, Germany). Samples of patient suspected of AML are collected by courier and shipped to LabPMM’s brand new testing facility in Germany. The results are reported back to the customer within five working days.

The AMLprofiler Assay is a microarray-based in vitro diagnostic (IVD) product for the detection of seven prognostic or diagnostic AML markers, including inv(16), t(15; 17), t(8;21), NPM1 insertion mutation A/B/D, CCAAT enhancer binding protein alpha (CEBPA) double mutation and clinically relevant high-ecotropic viral integration site 1 (EVI1) expression and low-brain and acute leukemia, cytoplasmic (BAALC) expression.

Henk Vietor, MD, PhD, the CEO of Skyline Diagnostics, said, "We have been commercializing the AML profiler as a diagnostic assay through our commercial network in Europe, which allows doctors to rely on accurate and fast testing of seven key markers in AML1. By launching this joint centralized testing service we can now also offer the qualities of our product to those laboratories and hospitals that do not wish to set up molecular testing themselves, with the same benefits: fast and reliable."

Jeffrey Edward Miller, PhD, CEO of LabPMM said, "We are excited about this collaboration since it represents the commercial launch of our Leukostrat FLT3 and NPM1 tests in Europe. While offering it as a testing service, it will be the only licensed and standardized, CE IVD registered testing available for FLT3 in Europe. It is our firm belief that a central standardized approach will facilitate the regulatory process and will have a very a real benefit for drug development, clinical trials, and, most importantly, patient outcome."

Related Links:
Skyline Diagnostics
Laboratory for Personalized Molecular Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
All-in-One Molecular System
AIO M160
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.